ストックスクリーナーアプリを入手
1.07
5.31%
-0.06
アフターアワーズ：
1.11
0.04
+3.74%
前日終値:
$1.13
開ける：
$1.12
24時間の取引高:
93,921
Relative Volume:
0.60
時価総額：
$34.10M
収益：
-
当期純損益:
$-60.70M
株価収益率:
-0.5245
EPS:
-2.04
ネットキャッシュフロー:
$-61.05M
1週間 パフォーマンス:
-5.31%
1か月 パフォーマンス:
-9.32%
6か月 パフォーマンス:
-25.17%
1年 パフォーマンス:
-46.23%
1日の値動き範囲:
$1.07
$1.12
1週間の範囲:
$1.07
$1.15
52週間の値動き範囲:
$0.87
$3.07
An 2 Therapeutics Inc Stock (ANTX) Company Profile
名前
An 2 Therapeutics Inc
セクター
電話
(650) 331-9090
住所
1800 EL CAMINO REAL, SUITE D, MENLO PARK
ANTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.07 | 34.10M | 0 | -60.70M | -61.05M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2024-08-09 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-12 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-01-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
すべてを表示
An 2 Therapeutics Inc (ANTX) 最新ニュース
Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - PR Newswire
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Aclaris Therapeutics, Inc. Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - marketscreener.com
Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - marketscreener.com
Allarity Therapeutics Announces First Patient Enrolled in - GlobeNewswire
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer - The Manila Times
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire
Certain Stock Options of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - The Malaysian Reserve
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - Insider Monkey
Xilio Therapeutics Announces Updated Phase 2 Data for - GlobeNewswire
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Yahoo Finance
Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS - PR Newswire
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - Business Wire
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - Yahoo Finance
Tango Therapeutics, Inc. Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients with MTAP-Deleted Glioblastoma and Other Solid Tumors - marketscreener.com
Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors - Yahoo Finance
Viking Therapeutics: A High Potential Biotech Play With Manageable Risks (NASDAQ:VKTX) - Seeking Alpha
Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks - simplywall.st
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment - Yahoo Finance
Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data - Business Wire
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - Yahoo Finance
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US - GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - GlobeNewswire
Cognition Therapeutics Reports Topline Results Showing Oral - GlobeNewswire
Cognition Therapeutics, Inc. (CGTX) Reports Topline Results Showing Oral CT1812 Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy - StreetInsider
Dogwood Therapeutics Announces First Quarter 2025 Financial Results - GlobeNewswire
Aligos Therapeutics, Inc. SEC 10-Q Report - TradingView
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - Yahoo Finance
PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
PTC Therapeutics, Inc. Announces Results from the Phase 2 PIVOT-HD Study of PTC518 in Stage 2 and Stage 3 Huntington's Disease Patients - marketscreener.com
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - The Victoria Advocate
TransCode Therapeutics (RNAZ) Adjourns Special Meeting to May 2 - GuruFocus
United Therapeutics Corporation Reports First Quarter 2025 Financial Results - Business Wire
Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Quantisnow
Protara Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - GlobeNewswire
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PR Newswire
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - Business Wire
Xilio Therapeutics to Present Updated Phase 2 Data for - GlobeNewswire
An 2 Therapeutics Inc (ANTX) 財務データ
収益
当期純利益
現金流量
EPS
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):